ACS Medicinal Chemistry Letters, published by the American Chemical Society, is a distinguished journal dedicated to advancing the field of medicinal chemistry. With impressive rankings in the 2023 category quartiles—Q1 in Drug Discovery and Organic Chemistry as well as Q2 in Biochemistry—this journal serves as a vital platform for researchers seeking to publish innovative findings and methodologies in drug development and therapeutic advancements. The journal's notable impact is reflected in its Scopus rankings, where it stands at #43 in Organic Chemistry and #45 in Drug Discovery. Although it does not currently offer open access, the contributions published from 2010 to 2024 provide a wealth of knowledge critical to both academia and industry. As a key resource for students, professionals, and researchers in the fields of chemistry and pharmacology, ACS Medicinal Chemistry Letters plays an essential role in shaping the future of medicinal therapeutics.

CURRENT ORGANIC SYNTHESIS, published by Bentham Science Publishers Ltd, is a leading journal in the field of organic chemistry and biochemistry that serves as a vital platform for researchers and professionals advancing the synthesis of organic compounds. With an ISSN of 1570-1794 and an E-ISSN of 1875-6271, it boasts a significant impact within its category, ranked in the Q3 quartile for both biochemistry and organic chemistry as of 2023. The journal covers innovative research and reviews that enhance our understanding of organic synthesis methodologies, showcasing contributions that advance the field. Operating from Sharjah, United Arab Emirates, CURRENT ORGANIC SYNTHESIS has evolved since its inception in 2005, providing access to a wealth of information essential for students, professionals, and researchers alike. While it currently does not offer open access, the journal continues to maintain a strong community of scholars dedicated to fostering dialogue and innovation in the organic sciences.

The Australian Journal of Chemistry, with an ISSN of 0004-9425 and an E-ISSN of 1445-0038, is a distinguished publication from CSIRO PUBLISHING, dedicated to advancing the field of chemistry since its inception in 1948. Based in Australia, this journal serves as a platform for original research articles, reviews, and innovative studies that encompass a wide spectrum of chemical disciplines, aiming to foster communication and collaboration among researchers globally. Despite its Q3 ranking in the Chemistry (Miscellaneous) category and standing at rank #236 in Scopus’ general chemistry classification, it remains an essential resource for professionals and students seeking to stay informed about emerging trends and discoveries in chemistry. The journal does not offer open access, emphasizing the premium quality of peer-reviewed content that adheres to rigorous academic standards. By bridging theory and practice, the Australian Journal of Chemistry continues to play a crucial role in shaping the future of chemical sciences.

TETRAHEDRON LETTERS, published by Pergamon-Elsevier Science Ltd, is a leading journal in the fields of Biochemistry, Drug Discovery, and Organic Chemistry, with a rich legacy since its inception in 1959. This prestigious journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of chemical sciences, featuring high-impact research that influences both academic and practical applications. Although it is currently classified in the third quartile across its categories for 2023, its rigorous peer-review process ensures the publication of quality research that contributes to the scientific community. With an ISSN of 0040-4039 and an E-ISSN of 1873-3581, TETRAHEDRON LETTERS is easily accessible for those in the academic landscape seeking to stay abreast of innovative developments. Researchers, professionals, and students alike will find invaluable insights and collaborative opportunities within the pages of TETRAHEDRON LETTERS, making it an essential read for anyone involved in the chemical sciences.

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

TETRAHEDRON, published by Pergamon-Elsevier Science Ltd, is a leading peer-reviewed journal that has been pivotal in advancing the fields of Biochemistry, Drug Discovery, and Organic Chemistry since its inception in 1957. With an ISSN of 0040-4020 and an E-ISSN of 1464-5416, this journal provides a platform for the dissemination of cutting-edge research and innovative methodologies that contribute significantly to the scientific community. Recognized for its rigorous editorial standards, TETRAHEDRON has been categorized in the Q3 quartile for 2023 across its relevant fields, reflecting its solid impact within the scientific sphere. Despite the current absence of Open Access options, the journal continues to engage a diverse readership, offering invaluable insights and advancements that fuel both academic and industrial applications. With an ongoing commitment to excellence, TETRAHEDRON remains an essential resource for researchers, professionals, and students aiming to stay at the forefront of chemistry and biochemistry research.

SynOpen is an esteemed open-access journal published by GEORG THIEME VERLAG KG, based in Germany, dedicated to advancing the fields of Biomaterials, Catalysis, Materials Science, and Organic Chemistry. Since its inception in 2017, the journal has established itself as a vital platform for researchers wishing to disseminate their findings in a rapidly evolving scientific landscape, earning a commendable Q2 ranking in Materials Science (miscellaneous) and Q3 in other key categories for 2023. With an increasing impact on its disciplines, SynOpen aims to foster interdisciplinary collaboration and innovation by providing unrestricted access to high-quality research, thus promoting a broader reach and visibility for authors. Scholars, professionals, and students alike can benefit from the comprehensive range of topics covered, as the journal's commitment to presenting cutting-edge studies and methodologies positions it as a crucial resource for contemporary scientific inquiry.

ARCHIV DER PHARMAZIE is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to pioneering advances in the fields of Pharmaceutical Science and Drug Discovery. With an impactful history dating back to its inception in 1822, this journal is recognized for its significant contribution to the pharmaceutical sciences, maintaining an impressive Q2 ranking in both the Drug Discovery and Pharmaceutical Science categories as of 2023. The journal’s commitment to excellence is reflected in its Scopus rankings, placing it in the top tiers of relevant fields, ensuring a broad reach and impact among researchers and professionals. Although Open Access options are not available, ARCHIV DER PHARMAZIE continues to be an invaluable resource for scholars seeking to stay abreast of cutting-edge research and developments in pharmacy and related sciences. The journal’s contributions not only serve as crucial benchmarks in research but also enhance the understanding of pharmaceutical innovations, making it essential reading for both seasoned professionals and students alike.

SYNTHESIS-STUTTGART

Published by the esteemed Georg Thieme Verlag KG, SYNTHESIS-STUTTGART stands as a vital resource in the field of Chemistry, specifically focusing on Organic Chemistry and Catalysis. With an impressive publication history dating back to 1970 and continuing through 2024, it serves as a platform for innovative research and developments in synthetic methodologies and their applications. The journal holds a significant impact factor, reflecting its influence within the academic community, and is recognized in the Scopus rankings as a reputable source in its categories, with a rank of #99/211 in Organic Chemistry and #43/68 in Catalysis. Researchers, professionals, and students alike can benefit greatly from its content, which upholds rigorous peer-review standards and contributes to the global discourse in these critical scientific domains.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.